How to Buy Weed in Cyprus: Medical Cannabis & the Island’s Divided Laws

Cyprus presents one of the most frustrating paradoxes in European cannabis policy. The Mediterranean island built a formal medicinal cannabis regulatory framework in 2019, layered on top of an exceptional-access pathway that had already been operating since 2016, yet patient access remains narrow, case-by-case, and administered directly through the Ministry of Health rather than through anything resembling a retail market.

For anyone researching cannabis dispensaries or hoping to purchase legal cannabis in Cyprus, the reality involves documented medical need, ministerial approval, strict criminal penalties for unauthorized possession, and the added complexity of an island where the Republic does not exercise effective control over the northern portion.

This guide covers what the law actually says, how the medical pathway works in practice, why the CBD and HHC situation is far stricter than most travel guides suggest, and what travelers carrying cannabis-based medicines need to arrange before they fly.

• Recreational cannabis is illegal throughout Cyprus. Cannabis is a Class B controlled drug in the Republic, and there is no legal recreational purchase or consumption pathway anywhere on the island.
• Cyprus permitted exceptional medical access from 2016 and adopted detailed Medicinal Cannabis Regulations in 2019 covering production, prescribing, and dispensing.
• Medical access runs through a documented request from the treating physician and, in current practice, an exceptional authorization process administered with Pharmaceutical Services.
• THC percentage alone does not make a CBD product lawful in Cyprus. Pharmaceutical Services treats CBD-containing products as medicinal products requiring marketing authorization.
• HHC is a controlled drug in the Republic of Cyprus and is not a legal alternative to cannabis.
• The 30-gram and three-plant figures relate to a legal presumption connected with intent to supply. They are not thresholds below which a fixed fine applies.
• Travelers carrying an internationally controlled cannabis-based medicine need authorization from Cyprus Pharmaceutical Services before arrival, and a foreign prescription alone does not authorize dispensing in Cyprus. 
• Controlled pharmaceuticals may not be moved across the Green Line into government-controlled areas.

Recreational cannabis is illegal in Cyprus. Medical cannabis is lawful only for patients who have obtained the required authorization, and even then it is dispensed through a controlled channel rather than a dispensary.

The distinction matters more here than in most European destinations, because several product categories that are openly sold elsewhere in the EU sit on the wrong side of Cypriot law.

• Recreational cannabis. Prohibited. Cannabis is classified as a Class B controlled drug under the Narcotic Drugs and Psychotropic Substances Law.
• Medical cannabis. Lawful for authorized patients. Access requires a documented medical justification submitted by a physician and approval through the Ministry of Health process.
• CBD products. Subject to product-specific regulation. Pharmaceutical Services classifies CBD-containing products as medicinal products requiring marketing authorization, so a low THC reading does not by itself make a product lawful to sell or import.
• HHC and related semi-synthetic cannabinoids. Controlled. Cyprus added hexahydrocannabinol to its controlled drugs schedule in 2023, and further legislation has listed related compounds.
• Personal cultivation. Prohibited. Licensed production exists as a legal framework, but there is no personal grow allowance at any plant count.

There is no coffeeshop system, no tolerance zone, and no tourist-facing legal purchase route. Anyone searching for how to buy weed in Cyprus should treat the honest answer as: not lawfully, unless you are an authorized patient going through the Ministry of Health channel.

The Republic of Cyprus is an internationally recognized state and an EU member. Its cannabis framework sits within the Narcotic Drugs and Psychotropic Substances Law, supplemented by the Medicinal Cannabis Regulations of 2019.

How the medical framework developed:

• From 2016. Pharmaceutical Services began granting named-patient exceptional approvals for cannabis products used for medical purposes. The Ministry’s 2023 annual report records 758 named approvals between June 1, 2016, and the end of 2023.
• 2019. Cyprus adopted detailed Medicinal Cannabis Regulations addressing production, prescribing, dispensing, and medical use, creating the structured framework the country operates under today.
• 2023. Hexahydrocannabinol was added to the controlled drugs schedule, closing the semi-synthetic cannabinoid loophole that had opened across parts of Europe.
• 2025. The Director of Pharmaceutical Services described the exceptional authorization pathway currently in use, under which physicians submit medically justified requests to the Minister of Health for patients with serious or chronic conditions.

On licensed cultivation. The 2019 regulations created a licensing framework for medical cannabis production. In August 2025, the Director of Pharmaceutical Services indicated that the cultivation provision had effectively remained on paper. Readers should not assume a domestic commercial cultivation industry is operating.

Cyprus is frequently described as having two legal systems, but the precise framing matters when the subject is criminal drug law.

The Republic of Cyprus is the internationally recognized state. The government does not exercise effective control in the northern part of the island, where Turkish Cypriot authorities administer a separate de facto system. The United Nations Security Council declared the 1983 declaration of the “Turkish Republic of Northern Cyprus” legally invalid.

What this means practically for anyone carrying cannabis or cannabis-based medicine:

• Do not carry anything across the Green Line. Republic of Cyprus Customs prohibits the movement of controlled pharmaceuticals, including narcotic drugs and psychotropic substances, across the Green Line into government-controlled areas.
• Crossing points are enforcement points. Treat them as you would an international customs checkpoint, including when traveling with a legitimate cannabis-based prescription medicine.
• Verify northern rules separately. Rules enforced in the Turkish Cypriot-administered north are administered independently, and travelers should confirm them directly rather than assuming they mirror or relax the Republic’s approach.
• An authorization from one side does not travel. A Republic of Cyprus import permit or medical authorization has no operative effect at a crossing point in the other direction.

Unauthorized cannabis possession is a criminal offense in the Republic of Cyprus. The penalty structure is often misreported in travel content, so here is the actual shape of it.

• Simple possession. For a Class B controlled drug, the statutory maximum for the simple possession offense is eight years’ imprisonment, a fine, or both. There is no fixed low-level fine band that applies automatically to small amounts.
• The 30-gram and three-plant figures. These quantities relate to a rebuttable legal presumption connected with possession with intent to supply. They do not define a lenient “small possession” category, and fewer than three plants does not create a lawful cultivation allowance.
• Possession with intent to supply. This carries a substantially more serious statutory maximum under the penalty schedule, potentially including life imprisonment, a fine, or both.
• A limited age-based rule. Where a person convicted of personal-use possession, use, or transport was under 25 at the time and has no prior drug-law conviction, any imprisonment imposed may not exceed two years.
• Circumstances drive outcomes. Quantity, intent, age, prior convictions, and the specific facts of the case can materially change both the charge and the sentence.

The practical takeaway for visitors is that Cyprus does not operate a de facto decriminalization regime. Enforcement discretion exists, but it is discretion within a serious criminal framework, not a fine schedule.

Understanding cannabis education resources helps, but nothing about the Cypriot medical pathway resembles a North American card program. There is no consumer-facing clinic model and no patient registry you can join on your own initiative.

What the 2019 regulations provide. Regulation 94 states that a cannabis-containing galenic preparation may be prescribed for an adult patient by the physician treating that patient, where the physician considers it appropriate. For patients under 18, the treating physician must submit a scientifically justified request to the competent authority.

What current practice adds. In 2025, the Director of Pharmaceutical Services described an exceptional authorization pathway under which doctors submit medically justified requests to the Minister of Health for patients with serious or chronic conditions. In practice, most access has moved through this documented, case-by-case channel.

What this means for patients:

• Your physician drives the process. The request is submitted by the treating physician with clinical documentation, not by the patient directly.
• There is no published closed condition list functioning as a checklist. Eligibility turns on documented clinical justification rather than a fixed table of diagnoses matched to specialist types.
• Approval is case by case. There is no standardized public timeline, and outcomes depend on the strength of the medical justification submitted.
• Dispensing is arranged, not retail. Pharmaceutical Services has reported forwarding approved prescriptions to cooperating pharmacies for dispensing, and has described measures taken to ensure the relevant preparations are present in Cyprus.

On availability. Cyprus does not have an ordinary retail cannabis market, and product range is narrow. But it is no longer accurate to say approved products are effectively unobtainable. Pharmaceutical Services has reported managing supply of medical cannabis oil extract for patients granted exceptional approval and arranging pharmacy dispensing for approved prescriptions.

Official guidance is published by the Ministry of Health through Cyprus Pharmaceutical Services, which is the authoritative starting point for any patient or physician question.

This is the single most commonly misreported point about Cyprus, and getting it wrong can put a traveler on the wrong side of the law while believing they are compliant.

CBD is not governed by a simple THC threshold. Pharmaceutical Services classifies products containing CBD as medicinal products requiring marketing authorization to be lawfully placed on the market. Unauthorized wholesale or retail sale is prohibited. A certificate of analysis showing a low THC figure does not establish that a product is lawful to sell, import, or carry into Cyprus.

Industrial hemp is a separate track. The Department of Agriculture describes industrial hemp for production and marketing purposes using a 0.2% THC threshold. That is an agricultural and production rule, not a general consumer-product allowance, and it does not convert a finished CBD product into an authorized item.

What travelers should do instead:

• Do not rely on a home-market certificate of analysis. It has no bearing on whether the product is authorized in Cyprus.
• Seek product-specific guidance before travel. Pharmaceutical Services and Cyprus Customs are the appropriate authorities for a definitive answer on a specific product.
• Expect customs scrutiny. Cyprus Customs lists narcotic drugs, psychotropic substances, and other controlled pharmaceuticals among import prohibitions except where the applicable authorization framework permits them.
• Do not treat pharmacy availability as blanket permission. The presence of some CBD products in the market does not mean every CBD product is lawful.

For a broader view of how cannabinoid rules differ across markets, Herb’s cannabis products coverage explains the categories you will encounter and how they are regulated elsewhere.

HHC is sometimes marketed across Europe as a workaround in restrictive jurisdictions. In Cyprus, it is not one.

Cyprus expressly added hexahydrocannabinol to Part II of the First Schedule of controlled drugs in 2023, and subsequent legislation has listed HHC alongside additional related compounds. Internationally, the UN Commission on Narcotic Drugs added hexahydrocannabinol to Schedule II of the 1971 Convention at its 68th session in March 2025, with the scheduling change taking effect on December 6, 2025. HHC has been reported across most of Europe and is listed as a controlled drug in the large majority of EU member states.

Treat HHC, and semi-synthetic cannabinoids generally, as controlled substances in Cyprus rather than as a gray-area product category.

Cyprus maintains strict enforcement at its points of entry, and a valid foreign prescription is not a travel document.

• Authorization is required in advance. Cyprus Pharmaceutical Services, through its Inspection Department, issues permits for visitors carrying small quantities of internationally controlled medicinal products for personal treatment. There is an official personal-use import application and published traveler guidance.
• Follow the current official procedure. Application requirements and lead times are set by Pharmaceutical Services and can change, so work from the department’s current instructions rather than a third-party checklist.
• A foreign prescription cannot be dispensed locally. Cyprus Pharmaceutical Services states that prescriptions for controlled drugs may be dispensed in the Republic only when issued by a doctor with a permanent address in the Republic. You cannot land in Cyprus and fill a home-country cannabis prescription at a local pharmacy.
• Carry your documentation. Keep the authorization, the prescribing documentation, and the medicine in its original labeled packaging together.
• Do not cross the Green Line with it. Controlled pharmaceuticals may not be moved across the Line into government-controlled areas, and an import permit does not change that.

Cyprus is not representative of the European cannabis picture. If access matters to how you travel, the contrast is worth understanding before booking.

Rules across these markets continue to shift, and residency conditions are the most common reason a visitor’s expectations do not match reality. Herb’s cannabis news coverage tracks European policy changes as they land.

Cyprus’s near-term trajectory appears focused on making the existing medical framework function rather than on recreational legalization.

• Implementation is the live issue. Patient advocates have pushed for clearer approval timelines, standardized pharmacy dispensing protocols, reliable supply arrangements, and training for healthcare providers.
• Cultivation remains largely unrealized. A licensing framework exists on paper, and the gap between that framework and actual domestic production has been acknowledged publicly by Pharmaceutical Services leadership.
• Regional precedent is building. Reforms in Malta and Germany have shifted the European conversation, though neither created a visitor-friendly retail market.
• EU context cuts both ways. Membership brings exposure to liberalizing trends, but also to pharmaceutical regulation that keeps CBD and cannabinoid products inside a medicinal framework.

No recreational reform is pending in a form travelers should plan around. Treat current law as the operating reality.

When dealing with regulatory environments as layered as Cyprus’s, access to clear and current information matters more than in mature markets. Herb provides educational resources that help readers understand laws, products, and consumption safely across jurisdictions.

• Strain and product knowledge. Explore thousands of cannabis strains and understand what legal markets actually offer.
• Educational content. Work through beginner guides covering cannabinoids, consumption methods, and quality indicators.
• European context. Compare policies in other destinations, including Portugal’s cannabis scene, to understand regional direction.
• Product education. Browse cannabis products to learn the categories and formats you will encounter where purchase is lawful.
• Policy updates. Follow cannabis news affecting legalization efforts worldwide.

For Cyprus residents working through the medical pathway, and for travelers planning trips to markets where access is lawful, Herb’s educational platform provides the foundation for informed decisions.

Cyprus is a superb Mediterranean destination, and cannabis access is not part of what it offers visitors. Here is how the decision breaks down:

• Traveling to Cyprus for a cannabis experience? There is no lawful route. No dispensaries, no coffeeshops, no tolerance zone, and a criminal framework with an eight-year statutory maximum for simple possession of a Class B drug.
• Considering CBD as a workaround? Do not assume a low THC reading makes a product lawful. CBD-containing products are treated as medicinal products requiring marketing authorization, and a certificate of analysis does not change that.
• Considering HHC as a workaround? It is a controlled drug in Cyprus and now scheduled internationally. This is not a gray area.
• A patient traveling with cannabis-based medicine? Arrange authorization with Cyprus Pharmaceutical Services before you fly, follow the department’s current personal-use import procedure, and do not expect to fill a foreign prescription locally.
• A Cyprus resident with a serious or chronic condition? The pathway is real but physician-driven. Start with your treating physician and the official Pharmaceutical Services guidance rather than a private clinic model.
• Crossing the Green Line? Do not carry cannabis or controlled cannabinoid medicines in either direction, regardless of what documentation you hold.

For destination guides covering markets where cannabis access is lawful and straightforward, Herb’s guides section has the full picture.